GLP-1 Companion Market: 11.3% CAGR to 2033?

The global GLP-1 companion products market reached $204.8 billion in 2025 and is forecast to reach $481.3 billion by 2033, reflecting an 11.3% CAGR. Growth is not a generic supplement story; it is a direct derivative of GLP-1 prescription volume, which exceeded 15.5 million U.S. adults in 2024. Companion products address therapy side effects such as muscle loss, nausea, constipation, and reduced fluid intake.

The Dietary Supplements Market provides the parent framework, but GLP-1 companions are a distinct demand pocket. Weight Management Nutrition Market participants are repositioning protein, fiber, and hydration SKUs around lean mass preservation. Retailers report that GLP-1 users spend 2.3x more on protein and fiber products than non-users.

North America remains the largest region at 42.0% of revenue, driven by U.S. GLP-1 penetration and pharmacy chains. Asia-Pacific is the fastest-growing at 13.1% CAGR due to rising obesity and diabetes prevalence. Margin pressure comes from protein input costs and retailer private label.

• GLP-1 users frequently under-consume protein because of appetite suppression, creating repeat purchase behavior for protein powders and RTD beverages.
• Digestive discomfort, especially constipation and nausea, drives demand for fiber and probiotic formats.
• Clinician guidance and telehealth weight-loss programs now include companion nutrition recommendations, expanding the addressable population.

Muscle Preservation Powders generated an estimated 34.1% of 2025 revenue, making it the largest segment in the GLP-1 companion products market. The Protein Powders Market is the core engine, but RTD protein beverages and protein bars are gaining share because they fit lower-volume eating patterns. Patients on GLP-1 therapy often cannot tolerate large meals, so convenient, high-protein formats command a premium.

• Protein powders retain the largest revenue base, supported by whey, casein, and plant protein blends.
• RTD protein beverages grew at 13.4% CAGR from 2020 to 2024, outpacing powder formats in convenience channels.
• Protein bars remain a smaller but high-margin format, with brands targeting 20-30g protein per bar for meal replacement use.
• Electrolyte Beverages Market products are moving from sports nutrition into GLP-1 companion sets because nausea and reduced fluid intake increase dehydration risk.

The digestive health segment is the second-largest at 22.4% share and is growing at 12.0% CAGR. Fiber supplements and probiotics are the primary beneficiaries. Margin pressure is moderate because raw material costs for inulin, psyllium, and probiotic strains have stabilized, but retailer private label now accounts for 18% of unit volume in U.S. drug stores.

The strongest driver is the expanding GLP-1 patient base. U.S. prescriptions for semaglutide and tirzepatide exceeded 15.5 million adults in 2024, and companion product attach rates are estimated at 28-34% depending on channel. Fiber Supplements Market demand is directly linked to constipation rates reported by 40-50% of GLP-1 users in patient surveys.

Probiotics Supplements Market growth is supported by digestive health positioning, but regulatory scrutiny is intensifying. In the United States, the FDA and FTC require substantiation for structure-function claims, and the EU EFSA has rejected several probiotic health claims. Whey Protein Market prices rose 12% year over year in 2024 due to dairy supply constraints, squeezing margins for protein powder brands that cannot pass through full costs.

• Claim substantiation costs for clinical studies can exceed $250,000 per claim, favoring larger brands.
• Texture and aftertaste issues limit plant protein adoption among users who already experience nausea.
• Retailers demand 15-25% trade margins, reducing profitability for small D2C entrants.

• Nestle S.A.: Leverages frozen and RTD formats through Vital Pursuit and Health Science channels, targeting nutrient density for GLP-1 users.
• Danone S.A.: Uses high-protein yogurt and medical nutrition brands to bridge clinical and retail weight management.
• Abbott: Scales Ensure and Glucerna into pharmacy and hospital channels, with strong protein and micronutrient credibility.
• Herbalife Ltd.: Deploys MLM coaches and protein shake subscriptions to reach weight management consumers.
• GNC: Uses specialty retail endcaps and private label to bundle protein, fiber, and hydration for GLP-1 users.
• Amway Corp: Converts direct sales relationships into recurring nutrition purchases, though clinical positioning is limited.
• Nature Made: Competes on vitamin and supplement trust in pharmacy and mass retail, with lower protein-specific differentiation.
• The Vitamin Shoppe: Curates GLP-1 companion bundles and subscription replenishment for fiber and protein.
• Conagra Brands Inc.: Positions frozen meals and snacks for grocery weight management, not clinical nutrition.
• Smoothie King: Sells functional smoothies and protein add-ins, capturing on-the-go GLP-1 users.

The Meal Replacement Products Market is a key battleground because GLP-1 users often replace meals with smaller, nutrient-dense options. Large food companies hold distribution advantages, while D2C brands move faster on formulation.

• 2024: Nestle S.A. launched Vital Pursuit, a frozen meal line positioned for GLP-1 users, signaling mainstream food entry into companion nutrition.
• 2024: Danone S.A. expanded high-protein yogurt and medical nutrition messaging around weight management and muscle preservation.
• 2025: Abbott introduced Ensure Max Protein positioning for muscle preservation, leveraging clinical trust and pharmacy distribution.
• 2025: GNC rolled out GLP-1 companion bundle endcaps, combining protein, fiber, and electrolytes in a single retail destination.
• 2025: Herbalife Ltd. added telehealth coaching to protein subscriptions, increasing retention among weight management consumers.
• 2025: The Vitamin Shoppe expanded D2C subscription replenishment, targeting repeat purchases for fiber and protein products.

North America remains the most mature market with $86.0 billion in 2025 revenue and a 10.2% CAGR. The U.S. accounts for the majority because GLP-1 prescribing is concentrated there, and pharmacy chains have integrated companion products into weight-loss programs.

• Asia-Pacific is the fastest-growing region at 13.1% CAGR, driven by rising obesity and diabetes prevalence in China, India, and Southeast Asia.
• Europe grows at 11.0% CAGR, supported by obesity care reimbursement and EFSA-compliant protein and fiber claims.
• LAMEA expands at 10.4% CAGR from a smaller base, with D2C and pharmacy chains improving access.
• North America faces regulatory stringency and market maturity, but retains the highest absolute revenue and margin pool.

M&A activity from 2023 to 2025 focused on protein powder and RTD beverage assets, as large food and nutrition companies sought GLP-1 companion exposure. Private equity and venture capital flowed into D2C nutrition brands with subscription models, especially those targeting muscle preservation and digestive health. Strategic acquirers included Nestle S.A., Danone S.A., and Abbott, while Herbalife Ltd. and GNC pursued partnerships rather than large acquisitions.

• Highest capital attraction: Protein Powders Market and Electrolyte Beverages Market, due to repeat purchase rates above 60% in subscription channels.
• Emerging interest: Fiber Supplements Market and Probiotics Supplements Market, as GI side-effect management becomes a standard companion recommendation.
• Deal structure: Majority stakes in D2C brands with $10-50 million revenue and gross margins above 55%.
• Strategic partnerships: Telehealth platforms and pharmacy chains now co-market companion bundles, reducing customer acquisition costs.

Three innovations are reshaping product development. First, precision fermentation whey and dairy proteins reduce reliance on animal supply chains, with commercial scale expected by 2027-2028. This directly affects the Whey Protein Market by offering price stability and sustainability claims.

Second, encapsulated probiotics and slow-release fiber matrices improve GI tolerance for GLP-1 users who experience nausea or constipation. Patent filings for encapsulated probiotic delivery increased 22% annually from 2020 to 2024.

Third, Personalized Nutrition Market platforms use intake tracking and GLP-1 side-effect data to recommend protein, fiber, and electrolyte doses. Adoption is early but growing at 18% CAGR among D2C subscribers. R&D spending among top 10 nutrition companies reached 4.5-6.0% of revenue in 2024, up from 3.2% in 2020.

• 2025-2026: Precision fermentation proteins enter premium RTD and powder formats.
• 2026-2027: Encapsulated probiotic and fiber blends become standard in digestive health SKUs.
• 2027-2028: Personalized Nutrition Market recommendations integrate with pharmacy and telehealth records.
• Incumbent risk: Large brands must acquire or develop these technologies to defend margin against agile D2C entrants.

• 1. Product
  • 1.1. Muscle Preservation Powders
    • 1.1.1. Protein Powders
    • 1.1.2. RTD Protein Beverages
    • 1.1.3. Protein Bars
    • 1.1.4. Others
  • 1.2. Digestive Health Products
    • 1.2.1. Fiber Supplements
    • 1.2.2. Probiotics Supplements
    • 1.2.3. Digestive Enzyme Supplements
    • 1.2.4. Others
  • 1.3. Nutrient Density Support
    • 1.3.1. Multivitamin Supplements
    • 1.3.2. Meal Replacement Products
    • 1.3.3. Others
  • 1.4. Appetite & Metabolic Support
    • 1.4.1. Satiety Support Products
    • 1.4.2. Appetite Management Supplements
    • 1.4.3. Others
  • 1.5. Hydration & Recovery Products
    • 1.5.1. Electrolyte Beverages
    • 1.5.2. Recovery Hydration Products
    • 1.5.3. Functional Hydration Mixes
    • 1.5.4. Others
  • 1.6. Others
• 2. Distribution Channel
  • 2.1. Hypermarkets & Supermarkets
  • 2.2. Pharmacies & Drug Stores
  • 2.3. Specialty Stores
  • 2.4. D2C
  • 2.5. Online (E-commerce)
  • 2.6. MLM (Direct Sales)
  • 2.7. Others

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific